Foster & Motley Inc. cut its stake in shares of Johnson & Johnson (NYSE:JNJ) by 1.9% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 57,050 shares of the company’s stock after selling 1,080 shares during the quarter. Johnson & Johnson comprises approximately 1.1% of Foster & Motley Inc.’s portfolio, making the stock its 24th biggest position. Foster & Motley Inc.’s holdings in Johnson & Johnson were worth $6,922,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other large investors also recently modified their holdings of JNJ. BlackRock Inc. increased its holdings in shares of Johnson & Johnson by 4.7% during the first quarter. BlackRock Inc. now owns 175,389,024 shares of the company’s stock valued at $22,476,102,000 after acquiring an additional 7,853,141 shares in the last quarter. Boston Partners increased its holdings in shares of Johnson & Johnson by 68.7% during the first quarter. Boston Partners now owns 12,783,909 shares of the company’s stock valued at $1,638,258,000 after acquiring an additional 5,207,124 shares in the last quarter. Cornerstone Wealth Management LLC boosted its position in shares of Johnson & Johnson by 10,307.6% during the second quarter. Cornerstone Wealth Management LLC now owns 2,497,098 shares of the company’s stock valued at $20,537,000 after buying an additional 2,473,105 shares during the last quarter. Bank of Montreal Can boosted its position in shares of Johnson & Johnson by 36.1% during the second quarter. Bank of Montreal Can now owns 6,910,459 shares of the company’s stock valued at $838,515,000 after buying an additional 1,833,622 shares during the last quarter. Finally, Summit Trail Advisors LLC boosted its position in shares of Johnson & Johnson by 11,692.6% during the first quarter. Summit Trail Advisors LLC now owns 1,767,832 shares of the company’s stock valued at $1,768,000 after buying an additional 1,752,841 shares during the last quarter. Hedge funds and other institutional investors own 66.67% of the company’s stock.
Several research firms recently commented on JNJ. ValuEngine raised Johnson & Johnson from a “sell” rating to a “hold” rating in a research report on Saturday, July 28th. Raymond James increased their price objective on Johnson & Johnson from $144.00 to $149.00 and gave the company an “outperform” rating in a research report on Wednesday. Credit Suisse Group set a $149.00 price objective on Johnson & Johnson and gave the company a “buy” rating in a research report on Sunday, October 14th. Sanford C. Bernstein began coverage on Johnson & Johnson in a research report on Wednesday, June 27th. They set a “market perform” rating and a $129.00 price objective on the stock. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Johnson & Johnson in a research report on Wednesday. Two analysts have rated the stock with a sell rating, eight have issued a hold rating and nine have given a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus target price of $141.54.
Shares of NYSE:JNJ opened at $139.50 on Friday. The stock has a market capitalization of $370.70 billion, a price-to-earnings ratio of 19.11, a PEG ratio of 2.19 and a beta of 0.70. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.33 and a current ratio of 1.65. Johnson & Johnson has a 52-week low of $118.62 and a 52-week high of $148.32.
Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, October 16th. The company reported $2.05 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.03 by $0.02. The business had revenue of $20.35 billion for the quarter, compared to analysts’ expectations of $20.05 billion. Johnson & Johnson had a return on equity of 32.79% and a net margin of 1.70%. The business’s revenue for the quarter was up 3.6% on a year-over-year basis. During the same period last year, the firm posted $1.90 earnings per share. As a group, equities analysts anticipate that Johnson & Johnson will post 8.14 EPS for the current year.
The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 11th. Shareholders of record on Tuesday, November 27th will be given a $0.90 dividend. The ex-dividend date of this dividend is Monday, November 26th. This represents a $3.60 annualized dividend and a yield of 2.58%. Johnson & Johnson’s payout ratio is 49.32%.
In other Johnson & Johnson news, CAO Ronald A. Kapusta sold 7,899 shares of the firm’s stock in a transaction dated Friday, September 7th. The stock was sold at an average price of $137.18, for a total value of $1,083,584.82. Following the transaction, the chief accounting officer now directly owns 25,725 shares of the company’s stock, valued at $3,528,955.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Michael E. Sneed sold 29,000 shares of the firm’s stock in a transaction dated Monday, August 27th. The stock was sold at an average price of $134.80, for a total value of $3,909,200.00. Following the completion of the transaction, the chief operating officer now directly owns 59,124 shares in the company, valued at $7,969,915.20. The disclosure for this sale can be found here. Company insiders own 0.22% of the company’s stock.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Read More: What is a Fiduciary?
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.